Work

Umibecestat in the API Generation program: Worsening in RBANS and/or CDR on treatment reverses after wash‐out

Year: 2020

Type: article

Source: Alzheimer s & Dementia

DOI: 10.1002/alz.041140

Authors: Ana Graf, Marie‐Emmanuelle Riviere, Fonda Liu, Marie‐Laure Rouzade‐Dominguez, Pilar Cazorla, Matt Quinn, Michal Arkuszewski, Javier Ricart, Jessica B. Langbaum, Hernan Piccard, Yihan Sui, Peter Quarg, Angelika Caputo, Eric M. Reiman, Pierre N. Tariot

Institutions: Novartis (Switzerland), Novartis (United States), Novartis (Spain), Banner Alzheimer’s Institute, Amgen (United States)

Language: English

Topic: Alzheimer's disease research and treatments

Subfield: Physiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3112810702

FWCI: 0.451

Cites:

Cited by: 7

Related to: 10